H-ras gene amplification or mutation is not common in human primary breast cancer.
- Authors:
- Published online on: September 1, 1999 https://doi.org/10.3892/or.6.5.1029
- Pages: 1029-1062
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
In a clinical study we found that patients with primary node negative breast cancer whose tumors showed high expression of H-ras had a significantly better prognosis than patients whose carcinomas did not. In the present study, these tissue specimens showed no H-ras gene mutation. The rate of gene amplification was 5% and did not correlate with the level of H-ras expression. These data indicate that increased expression and not amplification of the H-ras gene is valuable, if H-ras has a favorable role with respect to clinical outcome. This might be a general protective reaction as long as no mutation event has occurred in the H-ras gene.
